Guardant Health Raises $550 Million With No Regular Interest To Replace 2027 Debt

The cancer-testing company paid approximately $501.7 million to retire $395.2 million in debt principal and bought conversion protection.

Share
Guardant Health Raises $550 Million With No Regular Interest To Replace 2027 Debt

Guardant Health, which makes blood and tissue tests for cancer, completed a $550 million financing Monday with no regular interest, refinancing part of its debt due in 2027. The company said in its SEC filing that the new convertible notes — debt that can be exchanged for stock — mature in 2032.

$501.7 Million To Retire Old Debt

Guardant paid approximately $501.7 million to buy back approximately $395.2 million of principal on its existing convertible notes. Those older notes also carried no regular interest.

The financing produced approximately $538.3 million net after purchaser discounts, commissions and estimated expenses. Guardant used the remaining proceeds and existing cash to pay $51.7 million for options intended to cushion the cost of future conversions.

The final financing included a fully exercised $50 million purchaser option. Guardant had proposed a $500 million offering Wednesday, initially allowing any leftover proceeds to fund general corporate needs, potentially including acquisitions. Its subsequent pricing announcement specified the debt buybacks and conversion-protection purchases that the completed financing funded.

Conversion Protection Has A Ceiling

The new notes initially convert at approximately $208.95 per share, about 35% above GH shares' $154.78 price at Wednesday's close. Guardant can settle a conversion with cash, shares or a mixture of both.

Guardant expects the purchased options to reduce the dilution existing shareholders face when notes convert, or offset cash payments above the converted principal. That protection has an initial cap price of $309.56, a 100% premium to Wednesday's closing share price, and is subject to adjustments.

The options are separate from the debt and do not alter noteholders' rights. The new borrowing is unsecured, and its principal does not grow through accrued regular interest; additional or special interest can apply in specified circumstances.

Cancer Tests Across Stages Of Care

Guardant's business spans cancer screening, recurrence monitoring and treatment selection. Guardant360 helps doctors choose treatments for advanced cancer, while Guardant Reveal checks for residual or recurring disease in early-stage colorectal, breast and lung cancer.

Shield screens adults age 45 and older who have average colorectal-cancer risk. The company sells to oncologists, cancer centers and primary care physicians, and serves biopharmaceutical companies using its tests, data and analytics in drug development and clinical studies.

Guardant has retired the repurchased 2027 obligations; the new notes are due May 15, 2032, unless converted, redeemed or repurchased earlier.

Sources

More on Guardant Health

All Guardant Health (GH) coverage →